What is the use of Rybrevant 50 mg/ml Injection 7 ml?

Rybrevant 50 mg/ml Injection 7 ml used in the treatment of non-small cell lung cancer (NSCLC). Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, growing more slowly than small cell lung cancer.

Is a biomarker test required before receiving Rybrevant 50 mg/ml Injection 7 ml?

Rybrevant 50 mg/ml Injection 7 ml is an antibody targeting EGFR mutations. Your doctor may recommend a biomarker test to determine if this treatment is suitable for you. These tests identify specific biomarkers, including EGFR, to help guide the best treatment approach.

What does an EGFR mutation mean?

EGFR mutation is an alteration in the epidermal growth factor receptor (EGFR) gene, which can lead to uncontrolled cell growth and is commonly associated with cancers like non-small cell lung cancer (NSCLC).

What is non–small cell lung cancer?

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer. It grows more slowly than small cell lung cancer and includes subtypes like adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC is often diagnosed in later stages and may cause symptoms such as a persistent cough, chest pain, difficulty breathing, and weight loss.

Can Rybrevant 50 mg/ml Injection 7 ml be used during pregnancy?

Rybrevant 50 mg/ml Injection 7 ml is not recommended during pregnancy as it may harm the fetus. If you are pregnant or planning to become pregnant, inform your doctor before starting treatment.

How is Rybrevant 50 mg/ml Injection 7 ml administered?

Rybrevant 50 mg/ml Injection 7 ml is administered as an intravenous (IV) infusion by a healthcare professional. The dosage and frequency will be determined based on your medical condition and how you respond to treatment.

Is it safe to use other medicines with Rybrevant 50 mg/ml Injection 7 ml?

You are recommended to inform your doctor before using any other medicines with Rybrevant 50 mg/ml Injection 7 ml. This helps ensure that there are no potential interactions or adverse effects between Rybrevant 50 mg/ml Injection 7 ml and the other medicines you may be using.

Does Rybrevant 50 mg/ml Injection 7 ml cause skin problems?

Yes, Rybrevant 50 mg/ml Injection 7 ml may cause skin problems like rash, itching or dry skin. You may use alcohol-free moisturizing cream for dry skin. To prevent skin problems, wear protective clothing and use sunscreen. Also, limit your time in the sun during treatment and for 2 months after the treatment with Rybrevant 50 mg/ml Injection 7 ml. Consult the doctor if you have any skin reactions or concerns regarding this.

Rybrevant 50 mg/ml Injection 7 ml

₹95285

(Inclusive of all Taxes)

₹11434.2 Cashback (12%)

Written By ,

Reviewed By Santoshini Reddy G , M Pharmacy

Rybrevant 50 mg/ml Injection 7 ml used in the treatment of non-small cell lung cancer (NSCLC). It contains amivantamab, which works by blocking the signals that help cancer cells grow and divide. Common side effects may include rash, itching, muscle/joint pain, edema, shortness of breath, cough, constipation, changes in vision, chest discomfort, fever, and flushing. Inform the doctor if you are pregnant, breastfeeding, taking other medicines or have pre-existing medical conditions.

Know Your Delivery Time

Provide Delivery Location

Prescription drug

Whats That

Secure Payment

India's Most Trusted Pharmacy

Genuine Products

About Rybrevant 50 mg/ml Injection 7 ml

Rybrevant 50 mg/ml Injection 7 ml is a monoclonal bispecific antibody primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, growing more slowly than small cell lung cancer. It has several subtypes, including adenocarcinoma, squamous cell carcinoma, and giant cell carcinoma. Symptoms often include coughing, chest pain, and shortness of breath.

Rybrevant 50 mg/ml Injection 7 ml contains amivantamab, which targets and inhibits the activity of EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition factor), both of which are involved in cancer cell growth and spread. Rybrevant 50 mg/ml Injection 7 ml disrupts pathways that promote cancer cell growth, helping to reduce tumor size and slow disease progression.

In some cases, this medicine may cause side effects like rash, itching, muscle/joint pain, edema, shortness of breath, cough, constipation, changes in vision, chest discomfort, fever, and flushing. The majority of these side effects may not require medical treatment and will subside with time. However, if the side effects persist or worsen, see a doctor.

Rybrevant 50 mg/ml Injection 7 ml should not be received if you are allergic to it. Before starting treatment with Rybrevant 50 mg/ml Injection 7 ml, inform your doctor about any other medications or herbal products you are taking. Brief your medical history to the doctor in advance if you have a history of lung or breathing issues, skin disorders, eye problems, and liver/kidney impairment. Rybrevant 50 mg/ml Injection 7 ml is not recommended for use during pregnancy and breastfeeding. Also, it is not recommended for children, as its safety and efficacy have not been established.

Uses of Rybrevant 50 mg/ml Injection 7 ml

Rybrevant 50 mg/ml Injection 7 ml is used in the treatment of non-small cell lung cancer (NSCLC). The detailed use of Rybrevant 50 mg/ml Injection 7 ml is as follows:

Treatment of non-small cell lung cancer (NSCLC):Rybrevant 50 mg/ml Injection 7 ml is used in the treatment of non-small cell lung cancer (NSCLC). It targets specific pathways involved in the growth and spread of cancer cells, helping to control the progression of the disease. This treatment can help to control the disease and improve outcomes for patients with NSCLC.

Directions for Use

Follow your doctor's instructions on the dosage and timing of this medication.
Rybrevant 50 mg/ml Injection 7 ml is administered by the doctor or nurse in a healthcare setting.
Do not self-administer.

Medicinal Benefits

Rybrevant 50 mg/ml Injection 7 ml is used to treat non-small cell lung cancer (NSCLC). It specifically targets both the EGFR and MET receptors, which are involved in cancer cell development, resulting in a more precise treatment with fewer side effects than conventional chemotherapy. As a monoclonal antibody, it binds to specific cancer cell receptors, minimizing off-target effects. It slows disease progression and shrinks tumors by disrupting mechanisms that drive cancer cell proliferation. Rybrevant 50 mg/ml Injection 7 ml may also be effective for patients with specific mutations or who have developed resistance to other EGFR-targeted treatments.

How Rybrevant 50 mg/ml Injection 7 ml Works

Rybrevant 50 mg/ml Injection 7 ml contains amivantamab, which targets and inhibits the activity of EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition factor), both of which are involved in cancer cell growth and spread. Rybrevant 50 mg/ml Injection 7 ml disrupts pathways that promote cancer cell growth, helping to reduce tumor size and slow disease progression. Thereby, it helps treat Non-small cell lung cancer (NSCLC).

Storage

• Store in a cool and dry place away from sunlight.• Keep Rybrevant 50 mg/ml Injection 7 ml out of the sight and reach of children.• Cold chain - To be stored in cold places at 2ºC to 8ºC.

What if I have taken an overdose of Rybrevant 50 mg/ml Injection 7 ml

Rybrevant 50 mg/ml Injection 7 ml is administered in a controlled medical setting by a healthcare professional, and the likelihood of an overdose is much less. However, if you suspect an overdose or experience any adverse effects, seek medical attention immediately.

Drug Warnings

Brief your medical history to the doctor in advance if you have a history of lung or breathing issues, skin disorders, eye problems, and liver/kidney impairment. Individuals with pre-existing lung conditions should use Rybrevant 50 mg/ml Injection 7 ml with caution, as it may worsen lung symptoms or lead to interstitial lung disease (ILD). Rybrevant 50 mg/ml Injection 7 ml can cause fetal harm, so it should be avoided during pregnancy. Avoid breastfeeding during treatment with Rybrevant 50 mg/ml Injection 7 ml and for 3 months after the last dose. Rybrevant 50 mg/ml Injection 7 ml is not recommended for children, as its safety and efficacy have not been established. Seek medical attention if you experience symptoms of lung problems (shortness of breath, cough, or fever), skin problems (rash, itching or dry skin), or eye problems (eye pain, dry eyes, blurred vision, redness, changes in vision, itching, excessive tearing or sensitivity to light).

Diet & Lifestyle Advise

Consume a well-balanced diet that includes fruits, vegetables, lean proteins, and whole grains.
Meditation and deep breathing techniques can help you manage stress.
Limit processed and high-fat foods to maintain overall health.
Consume antioxidant-rich foods, such as berries and leafy greens, to help boost your immune system.
Use moderate skin care products and avoid sun exposure.
Limit or avoid alcohol during treatment.

Habit Forming

No

Therapeutic Class

ANTINEOPLASTIC

Alcohol

Consult your doctor

It is unknown if alcohol interacts with Rybrevant 50 mg/ml Injection 7 ml. Please consult a doctor if you have any concerns.

Pregnancy

Unsafe

Rybrevant 50 mg/ml Injection 7 ml is not recommended for use during pregnancy as it may cause fetal harm. Therefore, please inform your doctor if you are pregnant or planning to become pregnant before using Rybrevant 50 mg/ml Injection 7 ml.

Breast Feeding

Unsafe

It is not known if amivantamab passes into breast milk. Avoid breastfeeding during treatment with Rybrevant 50 mg/ml Injection 7 ml and for 3 months after the last dose.

Driving

Caution

Rybrevant 50 mg/ml Injection 7 ml may cause dizziness, tiredness or temporary vision problems. Avoid driving or operating heavy machinery if you experience any of these.

Liver

Caution

Inform your doctor if you have liver impairment. Your doctor will weigh the benefits and any potential risks before prescribing Rybrevant 50 mg/ml Injection 7 ml.

Kidney

Caution

Inform your doctor if you have kidney impairment. Your doctor will weigh the benefits and any potential risks before prescribing Rybrevant 50 mg/ml Injection 7 ml.

Children

Caution

Rybrevant 50 mg/ml Injection 7 ml is not recommended for children, as its safety and efficacy have not been established.

Heart

If you have heart problems, Rybrevant 50 mg/ml Injection 7 ml can still be used, but with careful monitoring and under strict medical supervision.

Geriatrics

Caution

Please inform your doctor if you are geriatric before administering Rybrevant 50 mg/ml Injection 7 ml, as there is limited information available on its safety in this age group.

Have a query?

FAQs

Country of origin

India

Manufacturer/Marketer address

Corporate Communications, Johnson & Johnson Private Limited., 501 Arena Space, Behind Majas Bus Depot, Off Jogeshwari Vikhroli Link Road, Jogeshwari (E), Mumbai 400 060

Other Info - RYB0008

Reference

Buy best Neoplastic Disorders products by

Welcome User

Rybrevant 50 mg/ml Injection 7 ml

Know Your Delivery Time

Secure Payment

India's Most Trusted Pharmacy

Genuine Products

Composition :

Manufacturer/Marketer :

Consume Type :

Return Policy :

Expires on or after :

FAQs

What is the use of Rybrevant 50 mg/ml Injection 7 ml?

How does Rybrevant 50 mg/ml Injection 7 ml work?

Is a biomarker test required before receiving Rybrevant 50 mg/ml Injection 7 ml?

What does an EGFR mutation mean?

What is non–small cell lung cancer?

Can Rybrevant 50 mg/ml Injection 7 ml be used during pregnancy?

How is Rybrevant 50 mg/ml Injection 7 ml administered?

Is it safe to use other medicines with Rybrevant 50 mg/ml Injection 7 ml?

What are the common side effects of Rybrevant 50 mg/ml Injection 7 ml?

Does Rybrevant 50 mg/ml Injection 7 ml cause skin problems?

Disclaimer

Reference